Cizzle Biotechnology Holdings PLC
CIZ
Company Profile
Business description
Cizzle Biotechnology Holdings PLC is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is correlated with early stage lung cancer.
Contact
C/o SGH Secretaries Limited
60 Gracechurch Street
6th Floor
LondonEC3V 0HR
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2
Stocks News & Analysis
stocks
What next for Tesla as 2024 deliveries disappoint?
Tesla shares started the year on a sour note. We think they continue to price in ambitious growth going forward.
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,511.90 | 46.90 | 0.55% |
| CAC 40 | 7,282.22 | 111.54 | -1.51% |
| DAX 40 | 19,906.08 | 118.58 | -0.59% |
| Dow JONES (US) | 42,732.13 | 339.86 | 0.80% |
| FTSE 100 | 8,223.98 | 36.11 | -0.44% |
| HKSE | 19,760.27 | 136.95 | 0.70% |
| NASDAQ | 19,621.68 | 340.88 | 1.77% |
| Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
| NZX 50 Index | 13,067.83 | 42.91 | -0.33% |
| S&P 500 | 5,942.47 | 73.92 | 1.26% |
| S&P/ASX 200 | 8,250.50 | 49.30 | 0.60% |
| SSE Composite Index | 3,211.43 | 51.13 | -1.57% |